Personalized melanoma vaccine cuts recurrence or death risk 42%
An international phase 3 trial found that adding a personalized mRNA melanoma vaccine to pembrolizumab reduced recurrence or death risk by 42%; regulatory review is next.
Topic
Intismeran Autogene
Topic
Intismeran Autogene
Moderna-Merck melanoma vaccine cuts death or recurrence 42%
In a phase 3 melanoma trial of more than 1,100 patients, intismeran autogene plus Keytruda cut the risk of death or recurrence by…
Personalized mRNA Vaccine Cuts Melanoma Relapse Risk 42% in Phase III
Intismeran autogene plus Keytruda cut melanoma recurrence or death risk 42% in the 1,137-patient Phase III INTerpath-001 trial, w…
Moderna Melanoma Vaccine Cuts Recurrence Risk 42% in Phase 3
Leaked phase 3 data show intismeran autogene plus Keytruda cut melanoma recurrence or death risk by 42%, below the 49% seen in ph…